The Southern California-based Optivus Parsons team will meet the market demand for the development of proton therapy using Optivus' patented and proven technology.
"The global success and leadership of Parsons guarantees our ability to develop multiple proton centers simultaneously with a consistent level of resources and integrity," said Slater.
"The Optivus Parsons teaming agreement is a milestone for both companies," said Small. "We share Optivus' dedication and commitment to patients who will benefit from the life-saving proton treatment technology for which they've set the gold standard."
Representatives from Parsons will be in attendance at the Optivus booth 501 during ASTRO for Q & A.
ABOUT OPTIVUS AND PARSONS
Optivus Proton Therapy, Inc. is a pioneer in the field of proton therapy technology. Optivus' patented, FDA-cleared modular Proton Beam Therapy System (PBTS), the Conforma 3000(R), leads the industry in patient throughput, highest operational reliability and safety. To date, the Optivus system has delivered nearly half a million individual patient treatments with a perfect safety record. For more information about Optivus, visit http://www.optivus.com.
Parsons, celebrating more than 60 years of setting industry standards, is a leader in many diversified markets such as healthcare, education and public buildings, infrastructure, water, transportation, construction, planning, commercial, industrial manufacturing, communications, environmental, life sciences, critical facilities, nuclear and special materials, and homeland security. Parsons provides technical and management solutions to private industrial customers worldwide, as well as federal, regional, and local government agencies. For more information about Parsons, visit http://www.parsons.com.
Contact:
Lisa Pizzi
Mark
'/>"/>
| SOURCE Optivus Proton Therapy, Inc. Copyright©2007 PR Newswire. All rights reserved |